Paper Details

  1. Home
  2. Paper Details

Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.

Author: FukayaSaki, FukuyasuAtsuko, HayashiKotaro, IshikawaTakeko, KamataMasahiro, MiyazakiMirei, MukaiKei, NagataMayumi, OhnishiTakamitsu, TadaYayoi, TanakaTakamitsu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case report describes a patient with BRAF-mutated melanoma who experienced elevated D-dimer levels and pyrexia after CombiDT and CombiEB treatments. Concomitant edoxaban prevented these adverse events, allowing the patient to continue receiving CombiEB.
Paper Details　
Original Abstract of the Article :
The combination of BRAF inhibitor and MEK inhibitor is one of the first-line treatments for unresectable BRAF-mutant melanoma or as an adjuvant therapy. However, some patients who received the combination of dabrafenib and trametinib (CombiDT) or the combination of encorafenib and binimetinib (Combi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/1346-8138.15813

データ提供：米国国立医学図書館（NLM）

Edoxaban: A Potential Solution for BRAF/MEK Inhibitor-Induced Adverse Events

This case report describes a patient with BRAF-mutant melanoma who experienced repeated episodes of elevated D-dimer levels and pyrexia after receiving combination therapy with BRAF and MEK inhibitors. Notably, concomitant administration of edoxaban, an anticoagulant, effectively prevented these adverse events. This study suggests a potential role for edoxaban in managing the side effects associated with BRAF/MEK inhibitor combinations, enhancing the tolerability and effectiveness of this important cancer therapy.

Managing Cancer Therapy Side Effects: A Multifaceted Approach

This case report highlights the need for a multifaceted approach to managing the side effects associated with cancer therapies. The authors' findings suggest that edoxaban could potentially play a crucial role in mitigating the adverse effects of BRAF/MEK inhibitor combinations, enhancing treatment tolerability and improving patient outcomes.

Edoxaban: A Potential Ally in Cancer Therapy

This case report sheds light on the potential of edoxaban in managing the side effects associated with BRAF/MEK inhibitor combinations. The authors' findings suggest that this anticoagulant could play a significant role in improving treatment tolerability and enhancing the overall efficacy of these important cancer therapies.

Dr. Camel's Conclusion

This case report offers a glimmer of hope for patients undergoing BRAF/MEK inhibitor therapy, suggesting that edoxaban could potentially play a crucial role in mitigating the adverse effects of these treatment regimens. It's like a guiding star in the desert of cancer therapy side effects, offering a potential solution for improving treatment tolerability and enhancing patient outcomes.

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2021-05-14
Further Info :

Pubmed ID

33600004

DOI: Digital Object Identifier

10.1111/1346-8138.15813

Related Literature

Article Analysis
・Effects of edoxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.